Sagimet Biosciences
SGMT • NASDAQ
Sagimet Biosciences is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO David A. Happel, with a market cap of $159.3M.
CEODavid A. Happel
Next Earnings
Upcoming earnings announcement for Sagimet Biosciences
Date
Thursday, May 7, 2026 (in a month)
Timing
Before Market Open (6:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.38
Earnings History
Past 11 earnings reports for Sagimet Biosciences
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 11, 2026 | Q4 2025 | -$0.29Est: -$0.41 | +29.3% | -Est: $1.3M | -100.0% |  10-K |
| Nov 13, 2025 | Q3 2025 | -$0.40Est: -$0.40 | 0.0% | - | — | 10-Q |
| Aug 13, 2025 | Q2 2025 | -$0.32Est: -$0.51 | +37.3% | - | — | 10-Q |
| May 8, 2025 | Q1 2025 | -$0.56Est: -$0.70 | +20.0% | - | — | 10-Q |
| Mar 12, 2025 | Q4 2024 | -$0.50Est: -$0.63 | +20.6% | - | — | 10-K |
| Nov 13, 2024 | Q3 2024 | -$0.45Est: -$0.42 | -7.1% | - | — | 10-Q |
| Aug 14, 2024 | Q2 2024 | -$0.25Est: -$0.33 | +24.2% | - | — | 10-Q |
| May 15, 2024 | Q1 2024 | -$0.23Est: -$0.40 | +42.5% | - | — | 10-Q |
| Mar 25, 2024 | Q4 2023 | -$0.34 | — | - | — | 10-K |
| Nov 13, 2023 | Q3 2023 | -$0.35 | — | $2.0M | — | — |
| Aug 21, 2023 | Q2 2023 | -$35.80 | — | - | — | 10-Q |